Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice

Purpose Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. Patients and methods Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most recent blood eosinophil count. Baseline variables predictive (P<0.05) of exacerbation in the outcome year were compared between patients who had two or more exacerbations and those who had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency or inpatient) or acute oral corticosteroid (OCS) course. Results Blood eosinophil count >400/µL (versus ≤400/µL) increased the likelihood of two or more exacerbations >1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); P<0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing age (per year), female gender (versus male), being overweight or obese (versus normal body mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 1.9-, or 3.1-fold, respectively (all P<0.05). Acute OCS use was the single best predictor of two or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 [95% CI: 3.50, 4.01]; P<0.001), and three or more courses increased the odds by >25-fold (OR: 25.7 [95% CI: 23.9, 27.6]; P<0.001). Conclusion Blood eosinophil count and several other variables routinely available in patient records may be used to predict frequent asthma exacerbations.

[1]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[2]  P. Gibson,et al.  Inflammatory phenotypes in adult asthma: clinical applications , 2009, The clinical respiratory journal.

[3]  E. Nizankowska-Mogilnicka,et al.  Frequent exacerbators – a distinct phenotype of severe asthma , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  A. Zwinderman,et al.  Severe adult-onset asthma: A distinct phenotype. , 2013, The Journal of allergy and clinical immunology.

[5]  Ruksha Bhadresha Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[6]  British guideline on the management of asthma. , 2014, Thorax.

[7]  J. Haughney,et al.  Current Control and Future Risk in Asthma Management , 2011, Allergy, asthma & immunology research.

[8]  D. Khatry,et al.  High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[9]  N M Rosenberg,et al.  Management of asthma. , 1992, Pediatric emergency care.

[10]  Sally E Wenzel,et al.  Recent asthma exacerbations: a key predictor of future exacerbations. , 2007, Respiratory medicine.

[11]  I. Pavord,et al.  Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk. , 2013, The Journal of allergy and clinical immunology.

[12]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[13]  D. Khatry,et al.  High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  Carlos A Camargo,et al.  Asthma exacerbations in North American adults: who are the "frequent fliers" in the emergency department? , 2005, Chest.

[15]  A. Zwinderman,et al.  Risk factors of frequent exacerbations in difficult-to-treat asthma , 2005, European Respiratory Journal.

[16]  P. Hansen Costs of Asthma , 1992, PharmacoEconomics.

[17]  A. Buist,et al.  Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. , 2007, Chest.

[18]  M J Hensley,et al.  Self-management education and regular practitioner review for adults with asthma. , 2002, The Cochrane database of systematic reviews.

[19]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[20]  Edwin J R van Beek,et al.  The clinical and genetic features of COPD-asthma overlap syndrome , 2014, European Respiratory Journal.

[21]  H. Aizawa,et al.  Characterisation of patients with frequent exacerbation of asthma. , 2006, Respiratory medicine.

[22]  C. Janson,et al.  Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. , 2013, The Journal of allergy and clinical immunology.

[23]  R. Louis,et al.  Importance of concomitant local and systemic eosinophilia in uncontrolled asthma , 2014, European Respiratory Journal.

[24]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[25]  N. Thomson,et al.  Identification and management of adults with asthma prone to exacerbations: can we do better? , 2008, BMC pulmonary medicine.

[26]  A. Chang,et al.  Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. , 2007, The Cochrane database of systematic reviews.

[27]  J. Fahy,et al.  Acute exacerbations of asthma: epidemiology, biology and the exacerbation‐prone phenotype , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.